Dr. Foldvari's research is supported by grants from Canadian Institutes of Health Research (CIHR), Canada Foundation for Innovation (CFI) and Natural Sciences and Engineering Research Council of Canada (NSERC). Dr Foldvari is a member of the American Association for the Advancement of Science, American Association of Pharmaceutical Scientists, American Society for Gene and Cell Therapy and the Controlled Release Society. She currently serves as Associate Editor of Nanomedicine: Nanotechnology, Biology and Medicine and perform editorial activity for the Journal of Nanomedicine and Biotherapeutic Discovery, Current Patents in Nanomedicine, Journal of Bionanoscience, Current Drug Delivery, and International Journal of Pharmaceutical Compounding.
Dr. Foldvari served as a grant reviewer on CIHR, NSERC, CFI and NIH panels and the Bill and Melinda Gates Foundation Global Health Initiatives review board. Dr. Foldvari is one of the Founding Directors of the American Society for Nanomedicine (ASNM) and the International Society of Nanomedicine (ISNM). She served as Board Member for Genome Prairie and was a Member of the Advisory Committee to the Prime Minister on Science and Technology and a Founder of the Canadian Society of Pharmaceutical Sciences (CSPS). She has received the YWCA Women of Distinction Award and the Sabex Award of Innovation. She is a frequently invited speaker at national and international conferences on gene and protein delivery systems and nanomedicine development and applications. Dr. Foldvari has authored more than 100 papers and 70 conference presentations and is the inventor on 18 patents.
Education
-
PhD,
Pharmaceutical
Sciences
College
of
Pharmacy,
Dalhousie
University,
Halifax,
Nova
Scotia
-
D
Pharm
Sci,
Doctorate
in
Pharmaceutical
Sciences
Summa
cum
laude,
Faculty
of
Pharmacy
Semmelweis
Medical
University,
Budapest,
Hungary
-
BSc,
Faculty
of
Pharmacy
Semmelweis
Medical
University,
Budapest,
Hungary
Positions and Honors
- 2007–to date Canada Research Chair in Bionanotechnology and Nanomedicine (CIHR, Tier 1), University of Waterloo
- 2006–to date Professor (tenured) of Pharmaceutical Sciences, School of Pharmacy, University of Waterloo
- 2007-to date Professor of Chemistry- cross appointment, University of Waterloo
- 2007-to date Professor of Chemical Engineering - cross appointment, University of Waterloo
- 2007–2010 Associate Director, Research and Graduate Studies, School of Pharmacy, University of Waterloo
- 2006–to date Adjunct Professor, College of Pharmacy and Nutrition, University of Saskatchewan
- 2006 Visiting Professor, Department of Chemical Engineering, Robert Langer’s Laboratory, MIT
- 2004–2006 Associate Dean Research and Graduate Affairs, University of Saskatchewan
- 1998–2000 Head, Division of Pharmaceutical Sciences, University of Saskatchewan
- 1999–2002 Vice President R&D, Helix BioPharma Inc.
- 1996–1999 Helix Chair in Industrial Pharmacy, University of Saskatchewan
- 1991–2002 President and Director R&D, PharmaDerm Laboratories Ltd.
- 1999–2006 Professor (tenured), College of Pharmacy and Nutrition, University of Saskatchewan
- 1991–1998 Associate Professor, College of Pharmacy and Nutrition, University of Saskatchewan
- 1988–1991 Assistant Professor, College of Pharmacy and Nutrition, University of Saskatchewan
Distinctions and Awards
- YWCA Women of Distinction Award Recipient (entrepreneur/innovator category), 1997
- Helix Chair in Industrial Pharmacy, University of Saskatchewan, 1996–1999
- Listing in A. Wood, Canadian Women Invent!, 2001
- Award of Innovation, University of Saskatchewan and Innovation Place, 2005
- Saskatchewan 25 Science Achievements, Government of Saskatchewan, Saskatchewan Centennial
- Sabex Award of Innovation
- YWCA Women of Distinction Award Recipient (Entrepreneur/Innovator Category)
- Scanning Microscopy International Presidential Scholarship for Conference Presentation Robert A. Chesebrough Gold Medal for Original Research on Vaseline® Petroleum Jelly (Third Place)
- Izaak Walton Killam Memorial Scholarship
Research Support
- Design and development of targeted gene delivery systems (CIHR): Regenerative Medicine and Nanomedicine - Innovative Approaches in Health Research Team Grant Program
- Micro- and nanoscale delivery systems for macromolecules: gene delivery (NSERC)
- Formulation and delivery of immunostimulatory oligodeoxynucleotides containing CpG motifs with carbon nanotubes against poultry diseases (NSERC): Collaborative Research and Development grant and the Agriculture Funding Consortium of University of Saskatchewan
- Transdermal delivery systems for protein medicines and vaccines (CIHR), Regional Partnership Program
- Cutaneous gene therapy for localized scleroderma: Development of novel delivery systems for the interferon gamma gene (CIHR): Institute of Musculoskeletal Health and Arthritis (IMHA) Strategic Initiative
Professional activities
- Honorary Editorial Board Member, Research and Reports in Transdermal Drug Delivery
- Editorial Board Member, Scientifica (Pharmaceutics Division)- 'The Open Access Journal of Science'
- Board Member, American Society for Nanomedicine
- Founding Director, American Society for Nanomedicine (ASNM)
- Board Member, International Society for Nanomedicine
- Member, Pachyonychia Congenita (PC) Consortium and Scientific Advisory Member for PC Project
- Associate Editor, Nanomedicine: Nanotechnology, Biology, and Medicine
- Hot Topic Editor, Current Drug Delivery
- Editorial Board Member, Journal of Nanomedicine & Biotherapeutic Discovery
- Editorial Board Member, Current Patents in Nanomedicine
- Editorial Board Member, Journal of Bionanoscience
- Editorial Board Member, Current Drug Delivery
- Editorial Board Member, International Journal of Pharmaceutical Compounding
Memberships
- American Association for the Advancement of Science
- American Association of Pharmaceutical Scientists
- Controlled Release Society
- American Chemical Society
- American Society of Gene & Cell Therapy
Research Entrepreneurship
Dr. Foldvari founded two spin-off companies that have commercialised drug delivery technologies she and her research group have developed.
PharmaDerm Laboratories Ltd.
